1216667-13-8
1216667-13-8
Chemical Structure
5-Hydroxyomeprazole-d3-1
- CAS No.: 1216667-13-8
- Formula:C17H16D3N3O4S
- Molecular Weight:364.43
IUPAC Name: (4-methoxy-6-(((5-(methoxy-d3)-1H-benzo[d]imidazol-2-yl)sulfinyl)methyl)-5-methylpyridin-3-yl)methanol
InChIKey: CMZHQFXXAAIBKE-BMSJAHLVSA-N
SMILES: CC(C(OC)=C(C=N1)CO)=C1CS(C2=NC3=CC(OC([2H])([2H])[2H])=CC=C3N2)=O
Biological Activity: 5-Hydroxyomeprazole-d3-1 is the deuterium labeled 5-Hydroxyomeprazole[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
5-Hydroxyomeprazole-d3-1 | 5-Hydroxyomeprazole-d3-1 is the deuterium labeled 5-Hydroxyomeprazole. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Hydroxyomeprazole (Standard) | ≥98% | 5-Hydroxyomeprazole (Standard) is the analytical standard of 5-Hydroxyomeprazole. This product is intended for research and analytical applications. 5-Hydroxyomeprazole is the major metabolite of Omeprazole (HY-B0113). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Hydroxy Omeprazole-d3 | 98.27% | 5-Hydroxy Omeprazole-d3 is deuterium labeled 5-Hydroxyomeprazole. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Hydroxyomeprazole | 96% | 5-Hydroxyomeprazole (Hydroxyomeprazole) is a major metabolite of Omeprazole (HY-B0113) through catalysis by CYP2C19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Hydroxyomeprazole sodium | 5-Hydroxyomeprazole sodium is the major metabolite of Omeprazole (HY-B0113). Measuring 5-Hydroxyomeprazole levels in plasma can determine the extent of Omeprazole metabolism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole | 99.32% | Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole magnesium salt | Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Omeprazole (Standard) | 99.86% | Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole also has neuroprotective and antibacterial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Omeprazole-d3 | 98.57% | Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole also has neuroprotective and antibacterial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Omeprazole-13C,d3 | 98.00% | Omeprazole-13C,d3 is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole also has neuroprotective and antibacterial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-O-Desmethyl omeprazole | 98.21% | 5-O-Desmethyl omeprazole is a metabolite of Omeprazole by cytochrome P450. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Esomeprazole | 96.41% | (R)-Esomeprazole ((R)-Omeprazole; (+)-Omeprazole) is an orally active cytochrome P450 2C19, CYP3A4, and CYP2C9-related metabolic modulator. (R)-Esomeprazole can be used in studies of digestive system diseases and compound metabolic interactions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Omeprazole impurity 4 | Omeprazole impurity 4 is an impurity of Omeprazole. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
